CAS: 1392116-14-1
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | JD-5037 REF: AN-AG01EONNCAS: 1392116-14-1 | 98% | 157.00 €~1,389.00 € | Thu 02 May 24 |
 | JD-5037 REF: TM-T4453CAS: 1392116-14-1 | 98.87% | 43.00 €~538.00 € | Wed 08 May 24 |
 | JD 5037 REF: 3D-FJ166461CAS: 1392116-14-1 | Min. 95% | To inquire | Wed 12 Jun 24 |
Ref: AN-AG01EONN
| 5mg | 157.00 € | |
| 25mg | 646.00 € | |
| 100mg | 1,389.00 € |
Estimated delivery in United States, on Thursday 2 May 2024
JD-5037
CAS:1392116-14-1
JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
Formula:
C27H27Cl2N5O3S
Purity:
98.87%
Color and Shape:
Solid
Molecular weight:
572.51
Ref: TM-T4453
| 1mg | 43.00 € | |
| 2mg | 57.00 € | |
| 5mg | 94.00 € | |
| 10mg | 139.00 € | |
| 25mg | 241.00 € | |
| 50mg | 362.00 € | |
| 100mg | 538.00 € | |
| 1ml*10 (DMSO) | 104.00 € |
Estimated delivery in United States, on Wednesday 8 May 2024
JD 5037
CAS:1392116-14-1
JD 5037 is a monoclonal antibody that inhibits the binding of endocannabinoids to their receptors. …
Formula:
C27H27C12N5O3S
Purity:
Min. 95%
Molecular weight:
645.73 g/mol
Ref: 3D-FJ166461
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Estimated delivery in United States, on Wednesday 12 Jun 2024
